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The change produced  in bacteria by growth  in specific immune sera  has been
studied for many years.  Metchnikoff  (1) in 1887  found that the virulence  of an-
thrax bacillus seemed  to be  diminished by growth in anti-anthrax serum.  Simi-
lar results were obtained by Charrin and Roger (2) and Roger (3)  with B. pyocy-
aneus, pneumococcus,  and streptococcus.  Later investigations,  however,  showed
that this apparent loss of virulence was due to the protective action of the immune
serum present, since bacteria, freed from the serum in which they had been grown,
showed  no  alteration  in  their  virulence  (Metchnikoff  (4),  Sanarelli  (5),  Issaeff
(6)  ).  The study of the effect  of this treatment  has been  confined  chiefly  to ob-
servations on B. cholera, B. typhosus, and other intestinal  organisms  (von Ransom
and Kitashima (7),  Muller (8),  Eisenberg (9), Walker (10),  Smith and Reagh (11),
and Feiler  (12) ).  Investigators  have found  that bacteria  grown  in homologous
immune sera,  or in the peritoneal  cavities  of immune animals,  show  marked in-
crease  in virulence  and in resistance  to bactericidal  action,  and  a loss  of agglu-
tinability.  The  increase  in  virulence  and  in  resistance  to  bactericidal  action
would  seem to indicate  a biological adaptation  on the part of the bacteria,  simi-
lar  to  the  process  of increased  resistance  which  the  animal  organism  develops
when invaded by infectious agents.  The loss of agglutinability  of the organisms
treated  with immune serum has been explained  as being possibly attributable to
an inadequate  receptor apparatus,  this condition having  been brought about  by
the  injurious  action  of  the  immune  serum  upon  the  organism.  Joos (13)  has
demonstrated  that  such  an  effect  is  brought  about by  heating  typhoid  bacilli.
He finds that the agglutinin-producing  substance, agglutinogen,  of typhoid bacilli
apparently consists of two elements, which he designates as a- and g-agglutinogen.
The a-agglutinogen is easily destroyed by heating at 60-620C.,  while  the fl-agglu-
tinogen  is heat-resistant.  Injection  of living  unheated  bacilli produces both a-
and  f8-agglutinins,  while  the  injection  of  heated  bacilli  produces  only f-agglu-
tinins.  Cole  (14)  has  found  that  inagglutinable  typhoid  strains  possess  less
power  to  absorb  agglutinins  than  do  normal  strains,  and,  when  injected  into
animals,  produce sera which are not as highly agglutinating, even for the injected
strain, as the sera produced  by highly  agglutinable  strains.  These  experiments
seem  to show  that  the  receptor apparatus  of the inagglutinable strains is not so
complete as that  of the  agglutinable bacilli.
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Recently  Friel  (15)  has found that by growing pneumococci  in  immune serum
they  became  agglutinable  and  phagocytable  in  normal  rabbit  serum, and  less
virulent  for mice than the untreated strains.
The  present  investigation  was  undertaken  in  order  to  study  the
different  types of  pneumococcus with regard  to this phenomenon and
to determine  whether  any  variation  of  type  organisms occurs  after
treatment with Antipneumococcus  Serum  I or II.
The experiments were  made  with virulent  strains of  the  pneumo-
coccus,  freshly  isolated  from  the  heart's  blood  of  mice  dead  from
pneumococcus  septicemia,  or obtained from blood  cultures from cases
of  lobar  pneumonia.  In  all  experiments  determinations  of  mor-
phology,  bile  solubility,  inulin  fermentation, capsule  formation,  viru-
lence, and agglutination were made before the strain was subjected to
treatment.  Cultures  were  then  made in normal  and immune  serum
bouillon,  and, in some instances,  as a control, in plain bouillon.  All
serum media were prepared by the addition of 0.5  cc. of  serum to 4.5
cc.  of  the  nutrient  beef  infusion  bouillon  used  for  routine  culture
medium,  the immune  serum bouillon  containing  one part in ten  of  a
highly potent antipneumococcus  horse serum, the normal serum bouil-
lon  containing  the  same  amount  of  normal  horse  serum.  Cultures
were  made  by  inoculation  of  0.5  cc.  of  a  bouillon  culture  of  the
strain  to  be  tested,  the  tubes  were  then  incubated  at  370C.  for  18
hours, and  after that  time  0.5  cc.  of this serum  culture  was  reinocu-
lated directly into another  tube of serum bouillon.  In some instances
cultures  were  transferred  daily,  in  others  at weekly  intervals,  being
kept  in  the  refrigerator  during  the  intervals  between  incubation.
Two different seriesof subcultures of each strain tested were employed,
one being  cultured consecutively in immune serum bouillon, the other
in normal  serum  bouillon.  The  manner  of growth  and  morphology
of  the  organisms  were  noted  each  time  that  a  culture  was  trans-
ferred.  It was noted that all strains grew luxuriantly under the con-
ditions  and  could  be kept  growing,  by  repeated  transfer,  for indefi-
nite  lengths  of time.  Two strains have now  been  grown under  such
conditions  for over  a  year.  Type  strains  grown  in the  homologous
immune  serum  showed  at first  complete  agglutination,  the  growth
sedimenting after  18 hours' incubation  in a hard mass which could  be
broken  apart only with difficulty.  After five or six transfers of Type
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I in homologous  serum,  the growth sedimented  in a  flocculent  mass
which  could  be  easily shaken  apart.  In  order  to produce  the same
effect with Type II organisms,  twelve  to fifteen  transfers  in immune
serum  were  necessary.  The  microscopic  picture  was  that  of  the
well known thread reaction,  individual organisms presenting a swollen
appearance  and  growing  in  long  chains  or  clump  formation.  All
strains  retained  the  original  characteristics  of  bile  solubility,  inulin
fermentation,  and  reaction  to  Gram  stain.  Marked  differences,
however,  between  the immune  and  normal serum  treated  organisms
were noted in growth on blood media, agglutination, capsule formation,
pathogenicity  for white  mice and  rabbits, and  antigenic and opsonic
reactions.
Type  strains  which  had been  grown  for  a number  of transfers  in
immune  serum  lost  the  characteristic  moist,  confluent,  greenish
growth on blood media  and grew in dry, isolated,  brownish colonies
which  showed  a tendency  to produce  hemolysis  of  the blood  cells in
the media.  When grown in plain bouillon subsequent to serum treat-
ment,  these strains  showed marked  sedimentation,  this characteristic
persisting  even  after  twenty-five  passages  in  plain  bouillon.  They
also  showed  less  tendency  to form  methemoglobin  than  the normal
serum  treated strains.
Variations in Agglutination.
The  change  noted  was  the  development  of  a  non-specific
agglutinative  reaction  by  the  immune  serum  treated  strains.
Those  strains  which  previously  were  agglutinable  only  in  the
homologous  serum,  subsequently  were  agglutinated  somewhat
less  completely  in  this  serum,  and  were  also  agglutinated  by
heterologous  immune  sera,  and  in  some  instances  even  by  normal
serum.  All agglutination  tests were made  according to the following
routine.  0.5  cc. of the  1: 10  serum culture was  inoculated into 5 cc
of plain bouillon; after this subculture had grown from  4 to  6 hours,
0.5  cc.  was  inoculated  into  25  cc.  of  plain  bouillon, and  this second
subculture incubated  for 18 to 20 hours.  At the end of that time the
bacteria were centrifugalized out, washed twice in saline, and an emul-
sion of these washed organisms in salt solution was used for the agglu-
tination  test.  In this way,  the error that would  result from the pres-
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ence  of  the immune  serum in  which  the  organisms  had  been  grown
was avoided.  It will be seen that the last subculture  contained serum
in  dilution  of  only  1: 5,000;  after  washing  twice  in saline  even  this
small amount  must  have been  largely removed.  Antipneumococcus
serum does not agglutinate in a dilution of immune serum higher than
1: 500, hence  the reaction obtained could not have been due to a small
amount  of  serum  adhering  to  the  bacteria.  Agglutinations  were
made with  the two types of antipneumococcus  horse serum, and with
normal  horse  serum.  In  each  case  one  tube  contained  equal  parts
of  the undiluted  serum and bacterial emulsion,  and the others 0.9 cc.
of serum dilution and 0.1  cc. of bacterial emulsion.  Tubes were kept
in a water bath at 37°C. for 2 hours, and over night on ice, and readings
were  taken at the  end  of  that  time.  Complete  reaction  (+  +)  was
recorded  when  the  bacteria  were  entirely  sedimented  with  marked
precipitation,  leaving  the  supernatant  fluid  clear;  almost  complete
(+  ),  when  the  bacteria  were  sedimented  with  less  marked  pre-
cipitation;  incomplete  (+),  when  marked  clumping  could  be  seen
but the clumps were still readily shaken from the bottom of the tube;
partial  (),  when  the  clumps  had  not  sedimented,  but  could  be
distinguished  macroscopically  as  a  fine  granulation;  negative  (-),
when  no  clumping  was present.
Table I shows the result of three agglutination tests, the organism in
each instance having descended  from  the same mouse  passage culture
of Pneumococcus Type I.  The original  culture showed typical agglu-
tination  reaction,  virulence,  and  protection  by  homologous  serum.
Subculture  A  was  grown  successively  in Immune  Serum  I bouillon,
Subculture  B  successively  in  normal  serum  bouillon,  Subculture  C
successively  in plain bouillon.  After  4  immune  serum  treatments,
Subculture  A  lost intensity  of  reaction  with  its  homologous  serum,
from complete to incomplete,  and became partially agglutinated with
the  heterologous  serum.  After  20  treatments in immune  serum  the
reaction was still incomplete  with the homologous  serum and had be-
come  almost complete  with the heterologous  serum.  After  15 trans-
fers in plain bouillon, subsequent  to 22  treatments in immune  serum,
the organisms had regained somewhat in intensity of reaction with the
homologous  serum,  but still agglutinated  partially  with the heterolo-
gous  serum.  Subcultures  B  and  C,  on  the  contrary,  maintained
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TABLE  I.
Agglutination  Tests  of Serum Treated Strain 1  114,  Pneumococcus Type  I,  114
Animal Passages,  before Serum Treatment.
Subcultures in each test were grown for two successive transfers in plain bouillon
subsequent  to serum  treatment  and  a  twice washed  emulsion  of centrifugalized
organisms was used.  Tube  1 in each case contained  0.3 cc. of bacterial  emulsion
and 0.3 cc.  of undiluted serum; the remaining tubes contained  0.9 cc. of serum di-
lution  and  0.1  cc.  of bacterial  emulsion.  Readings  were  made  after  the tubes
had  been kept in a water bath at 370C. for  2 hours and  over night on ice.
Subculture  A  Subculture  B  Subculture C
treatedin Immune Serum I  treated in normal serum.  untreated.
Serum  dilutions.
ImmuneImmuneal  mmuneImmune  Immune Immune  Normal
Serum  Serum  Seru  Serum  Serum  Serum  serum.
I.  II.  serum.  serum.  s
Strain I  1147*.  4  serum  treatments.
Nov.  6,  1915.
Undiluted.  +  ++  - - +  - -
1:10  +  - ++  - - +  - -
1:20  +  '++  - - ++  - -
1:40  +  - - +  - - ++  -
1:50  +  - - - - ++  - -
1:100  +-  -
1:200
1:400
1:500  -
Salt control.
. Strain  I  11423.  20 serum  treatments.
Nov. 30,  1915.
Undiluted.  +  ±+  - ++  - - ++  --  -
1:10  +  ++  - - ++  -- 
1:20  +  ++  ++  - - ++  -
1:40  +  +  ++  - - ++  -
1:50  +  +  - ++  - - ++  -
1:100  +
1:200  +
1:400  +
1:500  +
Salt control.
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TABLE  I-Concluded.
Subculture  A  Subculture  B  Subculture C
treatedin Immune Serum  um  ated in normal serum.  untreated.
Serum dilutions.
ImmuneiImmune.Immune  Immune  Immune  Immune'-----n Normal  mmune  e  Immune  Normal Serum  Serum  Serum  Serum  Serum  Serum  serum. I.  IL  I. r um ,  l II.  L  em
Strain I  11439.  15  transfers  in plain  bouillon  subsequent  to  serum  treatment.
Dec.  21,  1915.
Undiluted.  - -- +  - -
1:10  ++  +  - -
1:20  i+  +  - -
1:40  +  c  l  - -
1:50  +  +  - -
1:100  +  +
1:200  +
1:400
1:500
Salt control.
* In all the tables the numerals after the culture indicate the number of mouse
passages.  The  exponent indicates  the number  of generations removed  from  the
last passage.
throughout  the  course  of treatment  the  same intensity  of  reaction
with the homologous  serum and did not become  agglutinated  either
in the heterologous  or in  the normal  serum.
Table II shows the result of three agglutination tests made with two
subcultures,  both from the same mouse passage culture  of a  Pneumo-
coccus Type II,which showed typical agglutination reaction, virulence,
andprotection  before treatment.  Subculture Awasgrown successively
in Immune  Serum  II  bouillon,  Subculture  B  successively  in normal
serum  bouillon.  After  53  treatments  with  immune  serum,  Subcul-
ture A was  only partially agglutinated in the homologous  Serum  II,
but was  completely  agglutinated  in the  heterologous  Serum  I, and
incompletely  agglutinated  in normal  serum.  After  75  treatments in
immune serum, it was  still  only partially  agglutinated  in the homol-
ogous serum,  completely  agglutinated  in  the heterologous,  and,  this
time,  not agglutinated in normal serum.  After 47 transfers  in plain
bouillon  subsequent  to  serum  treatment,  the  partial  agglutination
with  the  homologous  serum  and  complete  agglutination  with  the
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Agglutination Tests  of Serum  Treated Strain II  34,  Pneumococcus Type  II,  34
Animal Passages,  before Serum Treatment.
The  same technique  was used as in the tests in Table I.
Subculture  A  Subculture  B
treated in  Immune  Serum  II.  treated  in normal  serum.
Serum  dilutions.
Immune  Immune  Normal  Immune  Immune  Normal
Serum I.  Serum  II.  serum.  Serum  I.  Serum II.  serum.
Strain II  3468
. 53  serum  treatments.
Oct.  1, 1915.
Undiluted.  ±+  +  ++
1:10  ++  +  - ++  -
1:20  ++  +  - ++  -
1:40  +  +  - ++  -
1:50  +  +  - ++  -
1:100  ++
1:200
1:400
1:500
Salt control.
Strain  II  349°.  75  serum  treatments.
Dec.  2,  1915.
Undiluted.  ++  - - ++  -
1:10  ++  - - ++  -
1:20.  ++  - - ++  -
1:40  ++  - - ++  -
1:50  ++  - - -
1:100  ++  -
1:200  - -
1  400
1:500
Salt control.
Strain II  34116.  47  transfers in plain  bouillon subsequent  to serum  treatment.
Dec.  2,  1915.
Undiluted.  ++  _-  ++  -
1:10  ++  - - ++  -
1:20  ++  - - ++  -
1:40  +  - - +±  -
1:50  +  - - ++  -
1: 100 
1: 200
1:400
1:500
Salt control.
55VARIATIONS  IN  PNEUMOCOCCUS
heterologous  serum  persisted.  In  this  experiment,  also,  the  or-
ganisms grown in normal serum were still completely agglutinatedwith
homologous serum and were in no instance agglutinated with the heter-
ologous  or normal serum.  It  is  to be  noted, however, in spite of the
incompleteness  of the  agglutination  of  the treated  organisms  in  the
homologous  serum,  that the agglutination  titer in homologous  serum
was  higher  than that in  heterologous  serum,  and  also  higher  than
that of normal untreated  strains in homologous  serum.
These tests  were  repeated  a number  of times  with many  different
strains, always with  the same result;  the longer a  strain was  treated
with its  homologous  serum,  the less  agglutinable  it became  in  that
serum, and the more agglutinable  in the heterologous  serum.  On the
contrary,  the  control  strains  cultured  in  normal  serum  and  plain
bouillon,  retained throughout  the  experiments  the  typical  agglutina-
tion with the homologous  serum  and were never agglutinated  by the
heterologous  or normal  serum.  It  was  also  noted  that the immune
serum treated strains sometimes were agglutinated  with normal horse
serum,  but  they  did  not  agglutinate spontaneously  in salt  solution,
nor  did  they  agglutinate  in other  immune  sera,  such  as diphtheria
and tetanus  antitoxin,  anti-influenza  serum, nor in an immune sheep
serum  obtained by the injection of  an  antigen prepared  by the  solu-
tion  of  pneumococci  in  sodium  cholate.  Bull  (16)  has  tested  an
immune  serum treated  strain of Type I and  found that it is aggluti-
nated in vivo and in vitro by normal rabbit  serum,  while  the  control
strain is not.
Variations  in Virulence.
Simultaneous  with  the  change  in  agglutinability,  the  immune
serum  treated  cultures  showed  a  pronounced  loss  of  virulence
for  white  mice  and  rabbits.  It  often  required  a  million
times  more  of  an  immune  serum  treated  culture  to  kill  than
of  the  control  normal  serum  treated  culture.  Virulence  tests  were
always  made with  cultures  at least  twice  removed  from  the  serum
treated  culture  in  which  1 cc.  contained  only 5,- part of  immune
serum.  As  0.1  cc.  of this  serum  is  required  to  protect  against  0.1
cc.  of a normal strain,  this loss of  virulence  cannot  be attributed  to
the  protective  value  of  the serum present.  In rabbits it was found
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that the washed bacteria  from  15  cc. of  a bouillon  culture of  treated
organisms would not kill, while 0.000005 cc.  of culture of untreated or-
ganisms killed in24hours.  In white mice it often required the bacteria
from 5 cc. of a culture of  treated organisms  to kill, while 0.000001  cc.
of  culture  of untreated  organisms  killed  in 24 hours.
Table  III  shows  the  comparative  virulence  of  the  immune  and
normal  serum  treated  cultures  of  Pneumococcus  Type  I and  Pneu-
mococcus Type II, the agglutination tests of which are given in Tables
I  and  II.  The  virulence  of  Subculture  I  114. B,  treated  12  times
with normal serum was such that 0.000001  cc.  of  a  20 hour  bouillon
culture  killed  in  56  hours,  while  the  fatal  dose  of  Subculture
A,  treated  12  times  with Immune Serum  I, was 0.5  cc.  of a 20 hour
bouillon  culture.  After 20 treatments with immune  serum, 1 cc. of a
broth culture of Subculture  A did not kill, and after 46 treatments the
TABLE  III.
Virulence of Serum Treated Strains  of Pneumococci.
The tests were  made by  intraperitoneal injection into white mice.  All  serum
cultures  were  transferred  at  least  twice  before  injection  into  such  amounts  of
bouillon  that  the  dilution  of  serum  in  the  culture  used  was at  least  1:5,000.
Autopsies were performed on all animals and smears were made from the peritoneal
exudate.  Pneumococci  were found  in all  cases.
Test I.
Virulence, Pneumococcus Type I.
12  serum  treatments.  20  serum  treatments.  46  serum treatments.
Amount of
culture  injected.  Treated in  Treated in  Treated in  Treated in  Treated in  Treated in
Immune  normal  Immune  normal  Immune  normal
Serum  I.  serum.  Serum  I.  serum.  Serum  I.  serum.
cc.
5.0  - I  D.  18 hrs.  -
1.0  - - S.*  - S.  -
0.5  D.  24 hrs.  - S.  - S.  -
0.1  S.  - S.  - - -
0.01  S.  - S.  - - -
0.001  S.  - S.  - - -
0.0001  S.  D.  18 hrs.  S.  D. 26 hrs.  - D. 36 hrs.
0.00001  D. 24hrs. t  "  56  "  - "  25  "  "  36  "
0.000001  - "  56  "  "  25  "  "  36  "
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TABLE  III-Concluded.
Test II.
Virulence Tests of Serum Treated Pneumococcus Type II  Made with Cultures Which
Had Received  27 and 61  Transfers in Plain Bouillon Subsequent
to 55 Serum  Treatments.
Virulence, Pneumococcus Type II.
27  transfers  in  plain  bouillon.  61  transfers  in plain  bouillon.
Amount  of
culture  injected.  Treated in  Treated in  Treated in  Treated in
Immune Serum II.  normal serum.  Immune Serum II.  normal serum.
cc.
2.0  D. 18 hrs.  - -
1.5  --  S.  -
1.0  S.  - S.
0.5  D. 36 hrs.  D. 18 hrs.  S.
0.1  S.  "  18  "  S.
0.01  S.  "  36"  - -
0.001  S.  "  24  "  - -
0.0001  - "  24  "  - D. 23 hrs.
0.00001  - "  20  - " 48  "
0.000001  - - -cc  "48"
* In the tables D.  stands for died;  S., for survived.  The figures  represent  the
number of hours  after  injection before  the death  of the animal.
t  No pneumococci  were  found in the heart's blood of this animal.
animal  receiving  the  bacteria  from  1 cc.  of  a  broth  culture of  Sub-
culture  A  survived.  Subculture  B,  however,  which was  treated  an
equal number  of times with normal  serum,  maintained  a  high viru-
lence,  0.000001  cc. of a broth culture killing regularly.
In Test II, Table III, is shown  the comparative virulence of an im-
mune  and  normal  serum treated  culture  of  Pneumococcus  Type  II
34.  Each  culture  had  received  55  serum  treatments  and  had  been
passed subsequently  through  a large  series of  broth transfers.  After
27 transfers in plain broth the fatal dose of the immune serum treated
culture was 0.5  cc.,  or more,  while  0.00001  cc.  of  the  normal  serum
treated strain killed a mouse in  20 hours.  After  61 transfers in plain
bouillon  1.5  cc.  of the immune  serum treated  culture  failed  to  cause
death, although 0.000001  cc.  of the normal serum treated  culture was
fatal  to a mouse  in 48 hours.
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It  will  be seen from these tables that the longer the pneumococcus
is grown in immune serum the less virulent it becomes,  while the same
strain grown in normal serum retains its original  virulence even after
long periods  of growth in plain bouillon.  The immune  serum treated
organisms  retain  the  avirulent  characteristics  after  as  many  as  75
transfers in plain bouillon subsequent  to serum treatment.  This fact
demonstrates conclusively that the loss  of  virulence  is not due to the
protective  action of the immune  serum present.
A study of the capsule formation in the immune  and  normal  serum
treated cultures demonstrated the interesting fact that while the latter
upon  injection  into  mice  formed  capsules  easily  demonstrable  by
the  Hiss  method,  the  immune  serum treated  organisms  showed  no
demonstrable  capsules under  similar conditions.  It  is  possible  that
the loss of virulence noted may in some way be related to the apparent
absence  of capsule  formation.
Variations in  Phagocytability.
The  phagocytability  of  the  organisms  grown  in  immune  serum
and  of  those  grown  in  normal  serum  was  tested  with
guinea  pig  leukocytes  in  the  presence  of  normal  and  immune
horse  serum  by  the  Neufeld  method.  The  organisms  grown
in  normal  serum  were  phagocyted  only  in  the presence  of  immune
serum.  Those grown in immune serum after at least  two subsequent
broth passages were phagocyted  in the presence of both immune and
normal  horse  serum.  The  organisms  grown  in immune  serum  were
also phagocyted in vivo in the normal rabbit; a reaction which does not
take  place  with the normal  virulent pneumococcus.  Growth in im-
mune serum has,  therefore,  made susceptible to the phagocytic  action
of  guinea  pig  leukocytes  a  culture  of  pneumococcus  previously  re-
sistant to such action.  This phenomenon  may also be related to the
loss  of  virulence  which  occurs  as  the  result  of  growth  in  immune
serum,  since  it  is  known  that  non-virulent  pneumococci  are  more
readily phagocyted  than highly  virulent strains.
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Variations in  Antigenic Properties.
In  order  to  test  the  possibility  of  variation  in  the  antigenic
properties  of  immune  serum  treated  strains,  two  antigens  were
prepared  in  the  following  manner.  Emulsions  of  washed  bac-
teria,  killed  by  heating  at  56°C.  for  45  minutes,  were  pre-
pared  from  equal  amounts  of  two  bouillon  cultures  of  Pneumococ-
cus Type  II  34,  one  of  which  had  been  treated  for  60  successive
transfers with  Serum II, the other  for the  same  number of transfers
with normal  horse  serum.  Immune  sera  were  prepared  from  these
antigens by intravenous  injection  of  rabbits.  The immunization  of
each  animal  was  carried  out  in  a  corresponding  manner,  and  the
serum  obtained  for the  tests  at  comparable  intervals  of time.  The
immune rabbit sera thus prepared  were tested for  their agglutination
reaction  with  normal  and  immune  serum treated  pneumococci  of
both Types I and II.
Examination  of Table IV shows that the immune response as meas-
ured by agglutinins is slower  in the rabbits immunized with immune
serum treated pneumococci  than in those immunized with the normal
serum treated  organisms.  It  is  further  evident  that  the serum  of
rabbits immunized  to immune  serum treated  Pneumococcus  Type II
contains  agglutinins for the immune serum  treated organisms  of both
Types I and II, but does not possess antibodies for the strains treated
TABLE  IV.
Agglutination Reaction of Sera from Rabbits Immunized  to  Normal and Immune
Serum Treated Strains of Pneumococcus Type II.
Agglutination Reaction of Sera Obtained 4 Weeks  after the Beginning of
Immunization.
Serum from  rabbits  Serum from  rabbits
immunized  with immune  immunized  with normal
serum treated  Pneu-  serum treated  Pneu-
Culture  used  for agglutination.  mococcus  Type II.  mococcus  Type If.
Rabbit  Rabbit  Rabbit  Rabbit
29C  30C  31C  32C
Normal  Pneumococcus  Type II  ...........  - ++  ++
Immune  serum  treated  Pneumococcus
Type II.
60LAURA  M.  STRYKER
TABLE  IV-Concluded.
Agglutination Reaction of Sera Obtained 6 Weeks  after the Beginning of Immuni-
zation,  Including Cross Agglutination Reactions with  Normal and
Immune Serum Treated Pneumococci Types  I  and II.
Serum from  rabbit immunized  Serum  from rabbit immunized
with immune serum treated  with normal  serum treated
Pneumococcus  Type II.  Pneumococcus  Type II.
Dilutions  of  serum.  Normal  Immune  Normal  Immune  Normal  Immune  Normal  Immune
Serum  Serum  Serum  Serum  Serum  Serum  Serum  Serum
Treated  Treated  Treated  Treated  Treated  Treated  Treated  Treated
Culture  Culture  Culture  Culture  Culture  Culture  Culture  Culture
II.  II.  I.  I.  II.  II.  I.  I.
Undiluted.  - +  --  +  +  +  - +
1:10  - +  - +  ++  +  - +
1:20  - +  +  ++  +  - +
1:40  - +  l+  +
1:50  +  +  +
1:100  +  +  +
1:200  +  - +
1:400  - - -
with normal  seruni.  On the other hand, the sera of  rabbits immun-
ized  to  a  Type  II pneumococcus  which  had been  grown  in normal
serum  for  a  similar number  of  transfers,  agglutinated  not  only  the
homologous  normal  strain, but reacted,  although  less  sharply,  with
immune  serum  treated pneumococci  of both  Types I and II.
Variations in Absorption Properties.
It has been demonstrated  by  Avery  (17)  that absorption of Anti-
pneumococcus  Serum  I  or  II  with  the  homologous  pneumococcus
removes  from  the  serum  all  agglutinins  for  the  homologous  organ-
ism, while  saturation of  Serum  I with  a Type II organism  does  not
remove  the  agglutinins  present  for  Type  I, and  the  same  result  is
obtained  when  an  attempt  is  made  to  exhaust  the  antibodies  of
Serum II with  Pneumococcus  Type  I.  Saturation of  the Antipneu-
mococcus  Serum  I  or  II with  homologous  immune  serum  treated
organisms,  removes  all  agglutinins  for  both  homologous  and  heter-
ologous  immune  serum  treated  pneumococci,  but  does  not  remove
the agglutinins  for the  homologous  normal  serum  treated organisms.
It is  also  found  that saturation of  antipneumococcus  serum  with
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the  homologous  type  of  normal  serum  treated  organisms  removes
the agglutinins  not only  for  these  pneumococci,  but  for  all immune
serum treated  strains.
Comparative Absorption  of  Antipneumococcus  Serum  with  Immune
Serum Treated and Normal Serum Treated Pneumococci.
Technique.-To 5  cc.  of  Antipneumococcus  Serum  II  was  added
the washed bacterial residue  from 25  cc.  of a  20 hour bouillon culture
of Pneumococcus Type II which had been treated for 65 transfers with
Immune Serum  II.  The  mixture was  kept  at  37°C.  for 30  minutes
and  for  18  hours  at  ice  temperature.  A  similar  mixture  was  pre-
pared by adding to the same amount of Serum II the bacterial  residue
from 25  cc. of a 20 hour bouillon culture  of a strain of Pneumococcus
Type II  which had  been  treated  for  65  transfers  with normal  horse
serum, and this mixture was also kept at 37°C. for 30 minutes and for
18 hours at ice temperature.  At the end of  that time  both mixtures
were  centrifugalized  and  the clear supernatant  fluids  again absorbed
with  fresh  bacterial  residues  of  the  immune  and  normal  serum
treated  cultures.  Agglutination  tests  were  then  made  with  these
absorbed  sera.
TABLE  V.
Agglutination of  Antipneumococcus  Serum II  before  and  after Absorption  with
Normal and Immune Serum Treated Strains of Pneumococcus Type  II.
After absorp-  After absorp-
tion with  tion with
Strains used  for  agglutinatin.  beforn.  normal serum  immune serum
absorption.  treated Type  treated Type
II.  II.
Pneumococcus  Type  II,  normal  serum
treated ...................  .............  ++  ++
Pneumococcus  Type  II,  immune  serum
treated ................................  ++  -
Pneumococcus  Type  I,  normal  serum
treated ...................  .............
Pneumococcus  Type  I,  immune  serum
treated .................................  +
Table  V gives  the  result  of  an  absorption  experiment  with Anti-
pneumococcus  Serum II.  Absorption  was repeated  until  the normal
serum treated organisms  had  absorbed from the serum all the  agglu-
tinins  for  this  strain.  This  serum then  had  lost,  also,  the  agglu-
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tinins  for  the  immune  serum  treated  organisms  which  it formerly
contained,  while  the  serum  which  had  been  absorbed  with  equal
amounts of  the immune serum treated organism,  although it had lost
the agglutinins  for  the homologous  immune serum  treated pneumo-
coccus,  still  retained  an  apparently  undiminished  quantity  for  the
homologous  normal  serum  treated  organism.
Reversion to  Type of the Altered Strains on Animal Passage.
Attempts were made to ascertain whether these variations in agglu-
tinability,  virulence, 'and  capsule  formation  would  persist  after  re-
peated  animal passage.  This study revealed  the fact that all strains
so  far  tested  reverted  to  the  original  type by  passage  through  the
animal  body, the number of passages  required  for  this reversion de-
pending  upon the number of treatments  in immune  serum which the
organism  had  received.  Strains  which  had  received  from  6  to  12
treatments  regained  virulence  and  specific  agglutinability  upon  1
animal  passage,  while  it required  3 or more  successive  passages  to
restore the virulence  and agglutinability  of strains which had received
from  50  to 100  serum  treatments.
TABLE  VI.
Effect  of  Animal  Passage upon  Agglutination and  Virulence  of Serum  Treated
Pneumococci.
Test I.
Agglutination and Virulence Tests Made  before and after Animal Passage of Cul-
ture I  1129,  Which Had Received  6 Serum  Treatments and  2
Passages in Plain Bouillon before Testing.
Amount of culture  Result  before  Result after  Result  before  Result after
injected.  animal passage.  animal passage.  animal passage.  animal passage.
Virulence  of organisms  treated  in  Virulence  of  organisms  treated
Immune  Serum I.  in normal  serum.
CC.
1.0  D. 16 hrs.  D. 18 hrs.  D. 16 hrs.
0.2  40  "  "  18  "  "  16"  -
0.1  "  40  "  "  18  "  "  16  "  D.  18 hrs.
0.01  S.  "  18  "  "  20  "  "18  "
0.001  S.  "  40  "  "  24  "  "20  "
0.0001  S.  "  22"  "  40  "  "  20  "
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TABLE  VI-Continued.
Agglutination of Culture I  1129,  before and after Animal Passage.
Culture treated  in Immune  Culture treated in normal serum. Serum I.
Serum used for agglutination.
Result before  Result after  Result before  Result after
animal passage.  animal passage.  animal passage.  animal passage.
Immune  Serum I ............  +  + +  + +  + +
69  "  "  II.  ..........  - -
Normal  horse  serum ..........  ++ 
Test II.
Agglutination  and  Virulence  Tests  Made  before  and  after  Successive  Animal
Passages of Culture I 114 62, Which Had  Received 59 Serum Treatments and
Subsequently 2 Passages in  Plain Bouillon  before Testing.
Result before  Result after  I  Result after
Amount of culture injected.  animal passage.  first animal  second  animal
passage.  passage.
Virulence  of  organisms  treated in Immune  Serum I.
Bacteria from 10 cc. culture ................  D. 16 hrs.
,  ,,  5  ,  ,  "  ".  16  '  _
2.0  cc.  culture ..........................  "  16  "  D. 16 hrs.  D. 36 hrs.
1.5  "  "  ..........................  S.  -
1.0  "  "  ..........................  S.  S.  S.
0.5  "  "...................  S.  -
0.14" ,  ",  . ...............  -.  -
0.001"  ".  .........................  - S.
Agglutination in Serum I ..................  +  +  ++
"  "  "  II ..................
"  " normal serum..............  -
Virulence  of organisms  treated  in normal  serum.
0.01  cc. culture ......................  D. 36 hrs.
0.001  "  "  .......................  "' 20 
0.00001  "  "  "  25  "  D.  22 hrs.
0.000001"  "  .................  36  "  21  "
Agglutination  in Serum I  ..................  + +  + +
"  "  "  II ..................  - -
"  " normal serum  ..............
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TABLE  vI--Concluded.
Test III.
Agglutination  and  Virulence  Tests  Made  before  and  after  Successive  Animal
Passages of  Culture II  34124, Which Had Received 109 Serum Treatments
and Subsequently 4 Passages in  Plain Bouillon before Testing.
Result  before  Result after  Result after  Result after Amount  of culture  injected,  e  first animal  second animal  third animal
Aonocudanimal  passage.  passage.  passage.
Organisms  treated  in Immune  Serum II.
Bacteria from 10 cc. culture....  D. 36 hrs.  - -
4"  "  5"  "  . .
2.0  cc. culture ..........  D.  D. 18 hrs.  -
1.0  "  "  ..........  S.  "  18"  _  _
0.5  "  "  ..........  "18"  -
0.1  "  "  ..........  " 18  "  D.16hrs.
0.001  "  "  ..........  "  18"  - D. 36 hrs.
0.0001  "  "  ..........  - " 36  "  D.  16hrs.  " 36  "
0.00001  "  "  ..........  - " 20"  " 36  "
0.000001"  "  ..........  - - "  24"  c  "  36  "
Agglutination  in Serum I .......  +  +  -
"  "  "  II......  ++  ++  ++  ++
"  " normal serum.  +  - -
Organisms  treated in  normal  serum.
0.01  cc. culture ..........  D. 16 hrs.
0.001  "  ........... "  "  16  "  _
0.00001  "  "  ..........  " 20  "  D.  24 hrs.
0.000001  "  "  ...........  "22"  " 36  "
Agglutination  in  Serum I ......  - -
"  I  .... II.  ++  ++
it  "  " normal  serum.  - -
Table  VI  shows  the  result  of  animal  passage  of  three  different
strains  of  immune  and normal  serum treated  pneumococci.  Test  I
shows the result of 1 animal passage of a Pneumococcus  Type  I which
had received 6 serum treatments, original virulence and typical agglu-
tinability  being  regained  upon  1 animal  passage.  Before  passage
it  required  0.1  cc.  of culture  of  the immune  serum treated organism
to kill  mice  in  40  hours,  and  the  organisms  were  agglutinated  with
Senrm II and normal  serum;  after passage 0.0001  cc. of  culture killedVARIATIONS  IN  PNEUMOCOCCUS
in  22  hours  and  the  bacteria  were  agglutinated  only  in  Serum  I.
Test  II  shows  the  result  of  3 animal  passages  of  a  Pneumococcus
Type  I which  had  received  59  serum  treatments.  In  this  case  it
required  3 animal  passages  to  cause  the  strain  to revert  to original
agglutinability, and  the virulence  had not been  materially  raised  by
this  number  of  passages.  Test  III  shows  the  result of  4  animal
passages  of  a Pneumococcus  Type  II which had received  109  serum
treatments.  With this strain 4 passages  were required to restore  the
original  agglutinability,  although  the  virulence  was  raised  by  1
passage.  In all  cases  control  tests were made with a normal  serum
treated  organism,  which had  neither  lost in virulence  nor in  specific
agglutinability.  A  great number of  similar  tests have  demonstrated
that these immune  serum treated strains are  readily caused  to revert
to the original  type  by animal  passage.
DISCUSSION.
The  effect  of  the  treatment  of  pneumococci  with  immune  serum
may be attributed to a suppression  of certain receptors,  similar to the
phenomenon  observed  by  Cole  with inagglutinable  typhoid  strains,
since  the serum treated  pneumococci  become  less  specifically  agglu-
tinable,  can no longer  absorb  the agglutinins  for  the normal  strains,
and, when injected into the animal body, do not produce agglutinating
sera  for  the normal  strains.
The  effect  produced  on the virulence  of  the pneumococcus  by im-
mune  serum treatment  is not  identical  with  that produced  in other
bacteria  by treatment  with  immune  sera.  The  pneumococcus,  in-
stead  of  becoming  more  virulent,  (serum-fast  or  immune)  with  im-
mune  serum  treatment,  becomes  much  less  virulent.  This  loss  of
virulence is one of the most noticeable effects of the treatment with the
immune serum  and, as mentioned before,  cannot be explained by the
protective  action of  the serum present,  since it persists after 60 or  70
transfers  in plain  bouillon subsequent  to serum  treatment,  when  the
amount  of  serum present in the culture  is too small to compute,  and
after  the organisms  have passed  through  so many generations  that
there could  surely be no immune substances  from the serum  still ad-
herent to them.  It would seem that some biologic  change must have
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taken  place in the organism,  transforming it from the virulent  to the
avirulent  type.  This  inference  is confirmed  by the  fact  that these
strains  rendered  avirulent have  lost capsules and  are  phagocyted  in
normal serum.
At present we have no explanation to offer in regard to this difference
between  the virulence  of the  typhoid bacillus and  the pneumococcus
when grown  in their immune  sera.  Since  antityphoid  serum is bac-
tericidal  and  reacts  best  in the presence of  complement,  and  since
antipneumococcus  serum possesses no demonstrable  bactericidal prop-
erties and its agglutinating  and protective  action is not increased  by
the  addition  of  complement,  it is possible  that the  different results
of  serum treatment  upon these  bacteria  with  such widely  separated
biologic  characteristics  may,  in  some  way,  be  attributable  to  the
differences  in the properties  of these  two sera.
It  is interesting  to note  that  the  variations  in  pneumococci  pro-
duced  by treatment with immune  serum do not persist  after animal
passage.  Very  few  passages  through  the  animal  body  cause  the
changed  organism  to revert  to  the  original  type  with characteristic
agglutinability,  virulence,  etc.
CONCLUSIONS.
1. The  growth  of  virulent  pneumococci  in  homologous  im-
mune  serum  produces  (a)  variations  in  agglutinability,  (b)  de-
crease in virulence,  (c) inhibition of capsule formation,  (d) increase  in
phagocytability  with  normal  serum,  and  (e) change  in  absorption
power  and  antigenic  properties.
2.  Reversion  to  the original  type  in  these  changed  forms  takes
place  upon  animal passage.
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